Linaclotide recommended in updated NICE IBS guideline

NICE guidance on the care of adults with irritable bowel syndrome (IBS) has been updated to include linaclotide as a treatment option.

IBS mostly affects people aged 20-30 years and is twice as commen in women as in men. | SCIENCE PHOTO LIBRARY
IBS mostly affects people aged 20-30 years and is twice as commen in women as in men. | SCIENCE PHOTO LIBRARY

The covers the support, treatment and advice patients with IBS should be offered by GPs, and the circumstances in which patients should be referred to a specialist for futher investigation.

The major change in the 2015 edition of the guideline is the recommendation of the guanylate cyclase C agonist linaclotide (Constella) as a treatment option for patients with IBS if:

  • optimal or maximum tolerated doses of previous laxatives from different classes have not helped, and
  • they have had constipation for at least 12 months.

GPs should review patients taking linaclotide after 3 months.

The 'initial assessment' section of the guidance has also been updated. In women with symptoms suggestive of ovarian cancer, the recommendation to carry out a pelvic examination has been replaced by the recommendation to measure serum CA125 levels, in line with the .

These changes are reflected in the quick-reference intelog guideline summary, which can be found online and in the forthcoming June print edition of intelog.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in